Short answer
OptimizeRx Corp (OPRX) filed an 8-K current report with the SEC on April 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Mary Varghese Presti appointed independent director through 2026 annual meeting.
OptimizeRx Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Mary Varghese Presti appointed independent director through 2026 annual meeting
- Board expanded to seven members from six, signaling ongoing governance refresh
- Audit Committee appointment adds an independent member to financial oversight
- Annual compensation includes $45,000 cash, approximately $175,000 equity, and $10,000 Audit Committee retainer
Item 7.01 · Regulation FD Disclosure
- Regulation FD disclosure furnished, not filed under Exchange Act Section 18
- Information generally excluded from Securities Act and Exchange Act incorporation by reference
- Limited liability and filing-use implications for investors evaluating the disclosure
Item EX-99.1 · Exhibit EX-99.1
- Mary Varghese Presti appointed independent director, advancing OptimizeRx’s board refresh and expansion
- Microsoft Health & Life Sciences COO adds expertise in AI healthcare platforms, commercialization, and operational efficiency
- Board gains M&A experience spanning strategic diligence, integration, portfolio scaling, and healthcare technology
- Appointment supports management’s shift toward an integrated, product-led platform with recurring and subscription-based revenue
- Strategic benefits remain forward-looking, with execution risks including regulation, customer concentration, cybersecurity, and competition
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OptimizeRx Corp 8-K filings
Get the next OPRX 8-K as it lands
Follow OPRX for push alerts, or ask the research agent what this filing means.